Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 55Recruiting 31Terminated 21Unknown 13Active not recruiting 9Not yet recruiting 6Withdrawn 2Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1

Interventions

pembrolizumab 3Drug Therapy 3Vincristine 2S 1 (combination) 2Nivolumab 2Gemcitabine 2Cyclophosphamide 2CA-4948 2Bevacizumab 2zimberelimab 1venetoclax 1tivozanib 1titanium silicide 1tisagenlecleucel 1sotigalimab 1propranolol CR 1prednylidene 1pimonidazole 1palbociclib 1mirdametinib 1imisopasem manganese 1gusacitinib 1fludarabine 1deltacortene 1brincidofovir 1axicabtagene ciloleucel 1atezolizumab 1Testosterone Propionate 1Testosterone 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Suspended × Temozolomide × Clear all
NCT04890093 2026-03-16

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
64 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡